Eyal Flom
Director/Board Member chez INNOCAN PHARMA CORPORATION
Fortune : 534 437 $ au 31/03/2024
Profil
Eyal Flom is currently the Director at Revium Recovery, Inc. He is also the Secretary & Director at InnoCan Pharma Corp.
and the Director at NurExone Biologic Ltd.
In the past, he served as the Legal Counsel at the Israeli Pharmaceutical Association.
Mr. Flom's former job includes being the Director at NurExone Biologic, Inc. Mr. Flom holds an MBA from the University of Derby and a graduate degree from Tel-Aviv University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 25/03/2024 | 2 375 277 ( 0,89% ) | 534 437 $ | 31/03/2024 |
Postes actifs de Eyal Flom
| Sociétés | Poste | Début |
|---|---|---|
| INNOCAN PHARMA CORPORATION | Director/Board Member | 25/09/2019 |
| REVIUM RECOVERY INC. | Director/Board Member | - |
| Israeli Pharmaceutical Association | General Counsel | 01/04/1995 |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The private company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Director/Board Member | - |
Anciens postes connus de Eyal Flom
| Sociétés | Poste | Fin |
|---|---|---|
| NUREXONE BIOLOGIC INC. | Director/Board Member | 08/05/2023 |
Formation de Eyal Flom
| University of Derby | Masters Business Admin |
| Tel-Aviv University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| REVIUM RECOVERY INC. | Distribution Services |
| INNOCAN PHARMA CORPORATION | Health Technology |
| NUREXONE BIOLOGIC INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Israeli Pharmaceutical Association | |
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The private company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Health Technology |
